VIM and metastatic neoplasm: The expression of vimentin, an intermediate filament protein, is associated with higher metastatic disease, and poor prognosis and survival of patients with multiple tumor types (Havel et al. 2015), including NSCLC patients (Soltermann et al. 2008; Dauphin et al. 2013).